JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266037

Human OGFR knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

OGFR KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 3. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human OGFR knockout HeLa cell line (AB266037)
  • Sanger seq

Unknown

Sanger Sequencing - Human OGFR knockout HeLa cell line (AB266037)

Homozygous : 1 bp deletion in exon 3

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 3

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266037-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266037 Human OGFR knockout HeLa cell line", "number":"AB266037-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266037-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266037-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266037 Human OGFR knockout HeLa cell line", "number":"AB266037-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266037-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266037-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266037 Human OGFR knockout HeLa cell line", "number":"AB266037-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266037-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266037 Human OGFR knockout HeLa cell line", "number":"AB266037-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
OGFR
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The Opioid Growth Factor Receptor (OGFr) is a protein that significantly influences cellular growth and regulation. Also known as zeta opioid receptor OGFr has an approximate molecular mass of 73 kDa. Researchers find this receptor in various tissues but it is most highly expressed in the brain and eyes. OGFr is a cytoplasmic and nuclear receptor indicating its versatile roles in different cellular compartments. It binds to the Opioid Growth Factor (OGF) also recognized as [Met^5]-enkephalin.
Biological function summary

OGFr regulates cell proliferation impacting both normal tissue maintenance and healing processes. This receptor functions as part of a complex with OGF thereby playing a fundamental part in the negative regulation of cell proliferation. By binding OGF OGFr enters the nucleus and modulates transcription events that influence cell cycle progression. OGFr activity affects diverse cells including those in corneal and epidermal tissues emphasizing its role in cellular homeostasis and repair mechanisms.

Pathways

OGFr integrates into the OGF-OGFr axis a pathway critical for the control of cell growth. This axis plays an important role in the regulation of both DNA synthesis and the cell cycle. OGFr interacts closely with the p16 and p21 proteins which are essential to the pathway's function in cell cycle modulation. The OGF-OGFr axis represents an important biological system that provides a means for cells to regulate their proliferation rate through receptor-ligand interaction.

Researchers have found that OGFr plays a significant part in the growth of various types of cancers such as squamous cell carcinoma and pancreatic cancer. Altered expression or function of OGFr may correlate with abnormal cell proliferation and tumor development. Moreover OGFr's relationship with proteins such as OGF and p21 highlights its potential role in therapeutics for these disease conditions. As targeting this pathway can modulate cell growth it presents a possible avenue for cancer treatment strategies.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com